Nanopharm-logo-with-signature-Pantone (1)
Search
Close this search box.

10 Oct 2024

Interview with Jane Provis Evans, Head cGMP services at Nanopharm

Share

Read the Interview

In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.

The Role of cGMP Testing in Pharmaceuticals

cGMP, or Current Good Manufacturing Practice, is a regulatory framework established by the FDA to ensure that pharmaceutical products are consistently produced and controlled according to quality standards. This is especially vital for OINDPs, as the delivery method must ensure consistent dosing and safety for patients. Jane emphasizes the role of cGMP testing in maintaining the high standards necessary for pharmaceutical quality control.

“cGMP testing is about more than just meeting regulatory requirements; it’s about ensuring that every batch of a drug is of the highest quality,” Jane explains. “This process ensures that every step, from raw material testing to the final product, meets rigorous standards.”

Assisting Clients in Developing Drug-Device Combinations

Nanopharm has always been at the forefront of helping clients navigate the complex landscape of OINDP development. this interview highlights how cGMP testing plays a pivotal role in this process, helping clients refine their formulations and ensure the consistency of their drug-device combinations. This is particularly crucial for OINDPs, where the interaction between the drug and its delivery device can significantly impact efficacy and patient outcomes.

“By conducting thorough cGMP testing, we can help clients identify potential issues in their drug formulations or devices early in the development process,” Jane says. “This proactive approach not only saves time and resources but also allows us to optimize their products to ensure they meet the necessary quality and regulatory standards.”

Nanopharm’s expertise in cGMP testing extends beyond quality control; it also plays a crucial role in the optimization phase. According to Jane, the company’s ability to provide robust analytical support means they can assist clients in refining their formulations, ensuring that the delivery mechanism of their drug-device combinations works seamlessly.

Expanding Capabilities with New GMP Services

Nanopharm’s recent introduction of new GMP services marks a significant milestone in its mission to support the pharmaceutical industry. These services are designed to provide end-to-end support for clients, from initial formulation development to the final stages of manufacturing.

In the interview, Jane explains why these new services could be a game-changer for clients, enabling them to transition from development to manufacturing more smoothly. “With our new GMP services, we can help clients take their products into patients more efficiently,” she explains. “We offer the expertise and infrastructure to conduct comprehensive cGMP testing and quality control, ensuring that all regulatory approvals are in place before products reach the market.”

The expansion of Nanopharm’s GMP capabilities allows the company to provide a seamless transition for clients who are looking to scale their products. This is particularly beneficial for startups or smaller pharmaceutical companies that may lack the in-house expertise or resources to navigate the complexities of cGMP regulations.

Building Expertise and Rigor in the Industry

As part of Nanopharm’s commitment to maintaining high standards, Jane places a strong emphasis on developing the skills of the team and continuously improving internal processes. “cGMP is not just about meeting regulatory requirements,” Jane notes, “it’s about building a culture of excellence and ensuring that our processes are constantly evolving to meet the highest standards.”

By investing in the professional development of their staff and refining their testing processes, Nanopharm ensures that they remain a trusted partner for clients in the pharmaceutical industry. Jane highlights the importance of maintaining a rigorous approach to cGMP testing, as it directly impacts the safety and efficacy of the end product. “Every step of the process needs to be meticulously planned and executed,” she says, “and that’s what our clients rely on us for.”

Why cGMP Testing is Essential for Patient Safety

At the heart of cGMP testing is the assurance that pharmaceutical products are safe and effective for patient use. For OINDPs, this means ensuring that each dose delivered through a nasal or inhaled device is consistent and reliable. The consequences of poor-quality control can be severe, potentially leading to suboptimal dosing or even harm to patients.

Jane underscores the importance of cGMP testing in this context, explaining that it serves as a safeguard against variability in drug production. “When it comes to pharmaceuticals, especially OINDPs, there is no room for error,” she stresses. “cGMP testing ensures that we can provide patients with the safest and most effective treatments possible.”

A Future-Forward Approach to Quality Control in Pharmaceuticals

Nanopharm’s new GMP services and ongoing commitment to quality control underscore its dedication to advancing the pharmaceutical industry. With Jane and her team leading the way in cGMP analysis, clients can be confident that their products will meet the highest standards of safety and efficacy.

As the industry continues to innovate, the role of cGMP testing will only become more crucial. Nanopharm’s emphasis on quality, rigorous processes, and a deep understanding of OINDPs positions them as a key partner in helping clients bring cutting-edge therapies to market. With the introduction of their new GMP services, Nanopharm is poised to continue playing a vital role in improving patient outcomes and helping to shape the future of OINDP drug development.

In a landscape where precision and compliance are paramount, Nanopharm’s expertise in cGMP testing offers a beacon of reliability. As Jane aptly puts it, “Our goal is to ensure that every product we work on meets the highest standards, because at the end of the day, it’s about getting the right treatment to the patients who need it.

Read the Interview

Related Posts

Innovation & Insights

Driving Innovation in Inhaled and Nasal Drug Product Development

Explore how Nanopharm, a globally recognized Contract Research Organization (CRO), is becoming the inevitable choice for inhalation and nasal drug product development. Under the leadership of Gemma Budd, the new General Manager, Nanopharm has established itself as a Centre of Excellence in Orally Inhaled and Nasal Drug Products (OINDP). With its state-of-the-art, purpose-built facility, Nanopharm offers comprehensive inhalation services, characterized by an in-depth understanding of OINDP science, products, and test methods.

Read More »